Table 2 Patient characteristics of the whole cohort. NOS: not otherwise specified, CC-Score: completeness of Cytoreduction score (0 stands for completed tumor resection). The data is shown as median and interquartile range or numbers with percentage of the whole cohort (n = 37 patients).
37 patients with PM from CRC | |
|---|---|
Age | 56y (43.5y – 63.5y) |
Gender (f/m) | 14 (37.8%)/23 (62.2%) |
T-stage of the primary tumor | |
T3 | 9 (24.3%) |
T4 | 28 (75.7%) |
N-stage of the primary tumor | |
N0 | 8 (21.7%) |
N1 | 13 (35.1%) |
N2 | 16 (43.2%) |
G-stage/histological grading | |
G2 | 16 (43.2%) |
G3 | 21 (56.8%) |
Histological subtype | |
Adenocarcinoma NOS | 31 (83.8%) |
Signet cell differentiation | 6 (16.2%) |
PCI | 7.5 (5–13) |
CC-score | 0 (100%) |
HIPEC regimen | |
MitomycinC/Doxorubicin | 25 (67.6%) |
Oxaliplatin | 12 (32.4%) |
PM occurence | 23 (62.2%) synchronous |
14 (37.8%) metachronous | |
RAS mutations | |
Wild-type | 18 (48.7%) |
KRAS mutation | 16 (43.2.8%) |
NRAS mutation | 3 (8.1%) |
No systemic chemotherapy prior CRS/HIPEC | 6 (16.2%) |
Neoadjuvant chemotherapy | 31 (83.8%) |
Douplet drug combination (FOLFOX/FOLFIRI) | 24 (64.7%) |
Triplet drug combination (FOLFOXIRI) | 7 (18.9%) |
Adjuvant/additive chemotherapy | |
First-line chemotherapy | 32 (86.5%) |
Single drug (Capecitabine) | 6 (16.2%) |
Douplet drug combination (FOLFOX/FOLFIRI) | 23 (62.2%) |
+ VEGF antagonist | 11 (29.7%) |
+ EGFR antagonist | 5 (13.5%) |
Triplet drug combination (FOLFOXIRI) | 3 (8.1%) |
+ VEGF antagonist | 2 (5.4%) |
No of cycles (median, IQR) | 6 (3–10) |
